health · family: it worked in the lab
blood cultures failthe smallest patients
345,000 newborns die of sepsis annually because blood cultures — the diagnostic gold standard — fail in the settings where mortality is highest
Problem statement
Neonatal sepsis kills an estimated 345,000 newborns per year globally — approximately 15% of all neonatal deaths. Low- and middle-income countries, particularly those in Africa, bear the greatest mortality burden. Blood culture, the diagnostic gold standard, serves these settings poorly: its sensitivity is suboptimal, it needs blood volumes that are difficult to obtain from infants, and its turnaround time is slow for a condition this urgent. Blood culture systems are also hard to implement in low- and middle-income countries because of high costs and limited laboratory infrastructure. In many settings, health-care workers rely on clinical assessment alone to decide whether to start antibiotics or refer a newborn to hospital.
Why this matters
Without diagnostic confirmation, clinicians in many settings treat on clinical assessment alone, which leads to unnecessary antibiotic use. This drives antimicrobial resistance — the WHO explicitly frames this TPP as an AMR intervention. An estimated 84% of neonatal infection deaths could be prevented through early diagnosis and appropriate management. The WHO's 2025 TPP defines two priority use cases — primary health care and hospital-level care — and describes current tests as inadequate or entirely lacking in many settings.
What’s been tried and why it hasn’t worked
Host-response biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) can indicate bacterial sepsis when they are built into hospital algorithms, but the WHO profile says they are not considered adequate to inform decisions in all situations and may be costly. Advanced molecular diagnostics face barriers such as affordability and reliance on positive blood cultures, and the WHO news release lists high costs and infrastructure requirements among the limits of current methods. In most non-hospital settings, the decision to start antibiotics and refer to hospital usually rests on clinical assessment. The WHO asks instead for an affordable standalone test that gives rapid results from 100 microliters or less of capillary blood and suits both hospital and non-hospital facilities.
What would unlock progress
The WHO TPP specifies: turnaround time of 30 minutes or less, sensitivity >=90%, blood volume of 100 microliters or less, functional at both point-of-care and hospital levels. The profile does not specify the analytical target or technology. Candidate routes include novel host-response biomarker panels that outperform CRP/PCT (likely multiplex combinations of cytokines, acute-phase proteins, and transcriptomic signatures) or microfluidic platforms that can detect pathogens directly from microliter blood volumes without culture. A student contribution could address the biomarker discovery side: systematically evaluating which combinations of commercially available biomarkers best discriminate bacterial sepsis from viral infection and non-infectious inflammation in neonates.
Entry points for student teams
A team could build a multiplex lateral flow prototype targeting 3-5 host-response biomarkers (e.g., CRP + PCT + IL-6 + IP-10) at neonatal volumes (<50 microliters from a heel prick) and validate it analytically on the bench — recombinant analytes spiked into a surrogate matrix at the concentrations the neonatal literature reports for septic and non-septic infants — characterizing limit of detection, cross-reactivity, and quantitative accuracy against the WHO TPP's stated bar of 30 minutes or less, sensitivity at or above 90%, and 100 microliters or less. The engineering challenge is maintaining quantitative accuracy across multiple analytes on a single low-cost strip, and that challenge is fully present on the bench. Benchmarking against clinical diagnosis in a neonatal unit is the study that ultimately matters, but neonates are the most protected research population and blood culture is itself an unreliable reference standard here, so the semester deliverable is that trial's design — reference-standard strategy, sample size, pre-registered analysis plan — written for a partner unit to execute. A third team needs only the published literature: extract reported biomarker distributions and ROC performance across the neonatal sepsis studies, model which combinations and cutoffs could actually reach the TPP's sensitivity target, and turn the result into a decision rule combining bedside signs with a rapid CRP — the antibiotic stewardship tool, derived from public data rather than from patient records no student team can obtain. Relevant disciplines: biomedical engineering, neonatology, immunology, data science.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "In vitro diagnostic tests for serious bacterial infection, including neonatal sepsis, among infants aged 0-59 days: target product profile," 2025, ISBN 9789240113015. WHO News, "WHO releases new target product profile for diagnostic tests to detect serious bacterial infections in young infants," Aug 6, 2025. go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- The WHO news release says health-care workers in many settings decide on antibiotics and referral by clinical assessment alone, which illustrates a diagnostic that exists in theory but not in practice.
- Structurally related to health-tb-poc-diagnostic-sputum-barrier (diagnostic designed for resourced settings fails in the settings with highest burden) and water-field-pathogen-detection (pathogen detection at point of need).
- The AMR framing is important: every neonate treated empirically without diagnostic confirmation contributes to resistance selection pressure.
Reconciliation 2026-08-21: Entry-point triage flag confirmed, and the unflagged second door failed the same test. The first door asked students to benchmark a prototype assay against clinical sepsis diagnosis in a neonatal unit — neonates are the most protected research population, and the comparator is a reference standard the brief itself describes as producing false negatives up to 60%. The second door, the machine learning stewardship tool, was not flagged in triage but silently required neonatal clinical records with bedside signs and CRP results, which are identifiable pediatric health data no student team can access. The assay door now ends at bench analytical validation against spiked recombinant analytes with the clinical benchmark restated as a design-the-trial deliverable, and the stewardship tool is now derived from published biomarker distributions and ROC data rather than from patient records. No named public neonatal sepsis patient dataset is cited: none was verified this session, and candidate repositories of clinical time-series data are credentialed-access rather than open, so the door rests on the peer-reviewed literature, which is public. The WHO TPP source URL cited above was re-checked by direct fetch and still resolves (HTTP 200).
Reconciliation 2026-09-29: Fact repair after a site review read this write-up against both of its sources. The WHO target product profile was read in full on 2026-09-29 (32-page PDF from https://iris.who.int/server/api/core/bitstreams/e231579b-7460-4ac3-9787-eea21a012ff3/content, which is the download linked from the cited WHO publication page). The WHO news release was read in full on the same day at the cited address. (1) The text gave sepsis incidence as 49-170 per 1,000 live births in low- and middle-income countries and 1-4 per 1,000 in high-income countries. Neither source gives incidence figures. The sentence now says what the profile says, that low- and middle-income countries, particularly those in Africa, bear the greatest mortality burden. (2) The text said blood culture is "functionally useless" and gave three figures: 68% of septic newborns with bacteremia below 10 CFU/mL, false-negative rates up to 60%, and results in 24-36 hours. None of these figures is in either source. The profile says blood cultures have suboptimal sensitivity, slow turnaround time and a need for blood volumes that are difficult to obtain from infants, and that they are hard to implement because of high costs and limited laboratory infrastructure. The sentence now says that. (3) The text described a study of 61 hospitals in four African countries in which 70% of newborns received antibiotics and 6% had a blood culture. Neither source mentions this study. The sentence was replaced with the news release's statement that health-care workers in many settings rely on clinical assessment alone, and the first working note above was changed to match. (4) "Broad-spectrum antibiotics for every febrile neonate" is not in either source, and the news release says health-care workers rely on clinical assessment alone "in many settings", not in low- and middle-income countries as a whole. The sentence now says clinicians in many settings treat on clinical assessment alone, which leads to unnecessary antibiotic use. (5) The text said primary care is "where most neonates first present" and that "no existing diagnostic meets the specifications" for either use case. Neither statement is in the sources. The sentence now uses the profile's wording, that current tests are inadequate or entirely lacking in many settings. (6) The paragraph on earlier attempts gave rise times for CRP (6-12 hours) and procalcitonin (2-4 hours), an accuracy range of 67-92%, and a statement that the fundamental constraint is biological. None of this is in either source. The paragraph now reports what the profile and the news release say about biomarkers, molecular tests and clinical assessment. (7) The text gave the profile's limits as under 30 minutes and under 100 microliters. The profile's essential criteria are 30 minutes or less and 100 microliters or less of capillary whole blood (Table 1, characteristics 6 and 8). Both places that quote the limits now say so. (8) The text said meeting the profile "requires either" new biomarker panels or microfluidic platforms. The profile states that it does not specify the analytical target or technology, so the two are now described as candidate routes. (9) The Source line abbreviated the news release title as "new TPP". It now carries the title as it appears on the page. Confirmed against the sources and left as written: the title, year and ISBN of the profile; the date of the news release, 6 August 2025; sepsis as roughly 15% of an estimated 2.3 million newborn deaths a year, which gives the 345,000 in the title by multiplication; the 84% of infection deaths that could be averted through early diagnosis and appropriate management; the two priority use cases; sensitivity of 90% or more; and the framing of the profile as a tool against antimicrobial resistance. Two things were left as written although the cited sources do not state them in these words. The sources do not call blood culture the "gold standard". The title says newborns die "because" blood cultures fail, while the sources say that tests are inadequate or lacking and that early diagnosis and management could avert most infection deaths. The figures removed in items 1, 2, 3 and 6 were not judged false. They may come from research papers that this write-up never cited, and they can be restored with a citation to the paper that reports them. One paper in the profile's reference list was checked for them (Gleeson et al., BMJ Global Health, 2024) and does not contain them. The earlier note dated 2026-08-21 refers to "false negatives up to 60%", a figure that is no longer in the text. NOT checked: the technical suggestions in the entry points section, such as the choice of IL-6 and IP-10 or a 50 microliter heel-prick volume, which are advice and are not attributed to the sources. Genes untouched.